We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $17.5 · 2 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 MSN
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key Support - Rectangle Pattern - thelegaladvocate.com
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key Support - Rectangle Pattern thelegaladvocate.com
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key Support - Low Vol ETF - thelegaladvocate.com
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key Support - Low Vol ETF thelegaladvocate.com
ARMP Stock Chart | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
ARMP Stock Chart | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) ChartMill
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Steep EPS Miss as Clinical-Stage Biotech Continues Heavy R&D Spending - Earnings Per Share - thelegaladvocate.com
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Steep EPS Miss as Clinical-Stage Biotech Continues Heavy R&D Spending - Earnings Per Share thelegaladvocate.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline Progress - thelegaladvocate.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline Progress thelegaladvocate.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | — | — | — | $420K | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 02. 24. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 01. 06. | Jones Trading | — | Initiate coverage | — → Buy | — | Jones Trading: Buy |
| 2025. 05. 20. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 12. 20. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 11. 15. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2024. 11. 13. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.